<DOC>
	<DOCNO>NCT01500590</DOCNO>
	<brief_summary>Diabetes lead cause chronic kidney disease develop country . About 30-40 % patient type 1 type 2 diabetes mellitus develop diabetic nephropathy . Microalbuminuria often use early predictor diabetic nephropathy . Many study already demonstrate renoprotective effect Renin-angiotensin-system ( RAS ) blockers patient vary degree albuminuria , study focus study decline glomerular filtration rate ( GFR ) among patient normoalbuminuria . However substantial number diabetic patient exist sub-normal GFR without microalbumin excretion . From literature , diabetes mellitus fast decline GFR investigator know whether decline slow use RAS blocker compare anti-hypertensive drug . This Study investigate effect early treatment RAS blocker decline rate GFR diabetic patient normoalbuminuria .</brief_summary>
	<brief_title>Effect Renin-angiotensin System Blockers Glomerular Filtration Rate Patients With Hypertension , Type 2 Diabetes With Normoalbuminuria</brief_title>
	<detailed_description>Renal excretory function , represent GFR , deteriorate age . After age 20-30 year , GFR decline 1ml/min per year . This age related loss renal function proportional blood pressure glycemic level , rate decline accelerate 10-12 ml/min per year poor BP glycemia control . ( 1 ) Such rate deterioration may lead end-stage renal failure need dialysis transplantation . Chronic kidney disease ( CKD ) define either presence kidney damage GFR &lt; 60 ml/min/1.73 m2 3 month . Kidney damage define pathological abnormality marker damage , include abnormality blood urine test image study . Microalbuminuria often early sensitive marker kidney damage many type chronic kidney disease . Among patient chronic kidney disease , stage divide stage 1-5 level GFR , high stage represent low GFR level . ( 2 ) Renin-Angiotensin System ( RAS ) enzymatic cascade angiotensinogen cleave renin form angiotensin I , turn , convert angiotensin convert enzyme ( ACE ) form angiotensin II . Angiotensin II produce renal vasoconstriction , block RAS show useful approach reduce renovascular risk . Among RAS block agent , angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) commonly use clinical practice . Many study already demonstrate renoprotective effect ACEI ARB . These study include MicroHOPE study ( 3 ) , IRMA ( 4 ) , IDNT ( 5 ) , RENNAL ( 6 ) subject vary degree albuminuria . With compelling benefit RAS blocker diabetic patient albuminuria , current guideline American diabetic Association ( ADA ) recommend use ACEI ARB delay progression renal disease diabetic nephropathy . ( 7 ) According National Kidney Foundation guideline , workgroup recommend hypertensive patient diabetes CKD stage 1-4 treated ACEI ARB , usually combination diuretic . ( 8 ) For patient suboptimal GFR ( &gt; = 60 ) without evidence kidney damage like microalbuminuria , consider CKD . There lack consensus selection anti-hypertensive medication group patient . For subject normoalbuminuria , BENEDICT study demonstrate delay onset microalbuminuria use either trandolapril alone trandolapril plus verapamil . ( 9 ) In ADVANCE trial , treatment fix combination perindopril indapamide reduce total renal event 21 % , define new worsen nephropathy development new microalbuminuria . ( 10 ) However study mainly focus use urinary albumin excretion outcome measure . They seldom take value GFR account . However study find significant decline GFR absence increase urine albumin excretion exist substantial percentage adult diabetes . ( 11 ) Decline GFR diagnostic prognostic value equivalent urinary albumin excretion . However literature , find effect RAS blocker decline GFR . We therefore would like carry study investigate whether RAS blocker delay progress renal disease , particular attention value GFR , patient GFR &gt; =60 without microalbuminuria .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Methyldopa</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Inclusion criterion : 1 . Age &gt; =35 80 year old capable give consent 2 . Chinese 3 . Either ( ) Type 2 diabetes mellitus ( DM ) diagnose accord ADA guideline ( ii ) Hypertension define systolic blood pressure &gt; 140 diastolic &gt; 90 mmHg take antihypertensive medication attain blood pressure level ( ) ( ii ) 4 . Estimated GFR ( eGFR ) ( base blood test take 3 month prior date consent ) 60 89 ml/min/1.73m2 calculate abbreviated 4 variable Modification Diet Renal Disease ( MDRD ) study equation identify cause renal insufficiency . 5 . Normoalbuminuria determine urine albumin creatinine ratio ( base urine test take 3 month prior date consent ) &lt; 2.5 mg/mmol men &lt; 3.5 mg/mmol woman first morning void urine sample . Exclusion criterion : 1 . Patients currently ACEI ARB antihypertensive medication 2 . Pregnancy 3 . Type 1 diabetes 4 . Nondiabetic renal disease include renal artery stenosis 5 . Secondary hypertension 6 . History symptomatic heart failure 7 . History myocardial infarction within 6 month 8 . Specific indication contraindication use ACEI ARB 9 . History allergy ACEI ARB</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>hypertensive</keyword>
	<keyword>without albuminuria</keyword>
</DOC>